Compare AbbVie Inc (ABBV) vs Cintas Corporation (CTAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Cintas Corporation — how do they compare? AbbVie Inc trades at $253.61 (market cap $449.91B), while Cintas Corporation trades at $181.36 (market cap $72.76B). The key difference: AbbVie Inc is far larger — about 6.2× Cintas Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | CTAS | |
|---|---|---|
Market Cap | $449.91B | $72.76B |
Sector | Health | Industrials |
52-Week High | $261.07 | $226.27 |
52-Week Low | $184.85 | $163.55 |
Enterprise Value | $513.38B | $75.49B |
Dividend Yield | 2.72% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
CTAS trades at $181.83, up 0.29% with a bullish technical signal. The stock shows strong fundamentals with revenue growing from $7.9B in 2022 to $10.3B in 2025 and net income margins expanding to 17.57%. Recent earnings mostly beat expectations, and the company maintains a 43-year dividend growth streak. Positive sentiment is supported by analyst coverage and recent corporate recognitions.
Outlook remains positive with a consensus price target of $212.50, implying 17% upside. Risks include elevated valuation multiples (P/E 37.6) and integration challenges from the UniFirst acquisition. The stock offers growth and income appeal but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
